GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Conference Details: | ||||
Fireside Chat | ||||
Date: | Wednesday, November 20, 2024 | |||
Time: | 11:00 – 11:25 a.m. Greenwich Mean Time | |||
Location: | London, United Kingdom | |||
Moderator: | Roger Song, MD, CFA, Equity Analyst | |||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Additional Management Team Members | |||
Investor Meetings | ||||
Date: | Wednesday, November 20, 2024 | |||
Recordings
A replay of the fireside chat will be available on the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Giovanna Chandler
202-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.34 |
| Daily Change: | 0.15 2.09 |
| Daily Volume: | 8,419,158 |
| Market Cap: | US$1.180B |
May 19, 2025 April 29, 2025 April 15, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
